anonymous
Guest
anonymous
Guest
Total revenues declined 5% year-over-year to $12.68 billion from $13.3 billion in the third quarter of 2018.
Segment-wise, Biopharma revenues grew 7% annually to $10.1 billion, while Upjohn revenues dropped 26% to $2.19 billion. Consumer Healthcare revenues were down 55%.
Pfizer management revised up its full-year earnings and revenue guidance.
Segment-wise, Biopharma revenues grew 7% annually to $10.1 billion, while Upjohn revenues dropped 26% to $2.19 billion. Consumer Healthcare revenues were down 55%.
Pfizer management revised up its full-year earnings and revenue guidance.